LPA1 Modulation: Admilparant’s Role in the Evolution of IPF and PPF Therapies

Innovative Therapy Shows Promise in Reversing Lung Scarring in Idiopathic Pulmonary Fibrosis - Phoenix Bioscience Core

Facebook Twitter LinkedIn Email Print Ken Knox, MD, and Timothy Marlowe, PhD, are innovating therapies to better treat IPF. Researchers develop FN-2012, a novel treatment that could transform the management of IPF and other fibrotic diseases Idiopathic pulmonary fibrosis (IPF) is a lung disease that progressively scars the lungs, making it harder to breathe. According to the Pulmonary Fibrosis Foundation, more than 250,000 Americans are living w…

LPA1 Modulation: Admilparant’s Role in the Evolution of IPF and PPF Therapies

Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) through myofibroblast differentiation and ECM production. Admilparant shows promising antifibrotic activity in preclinical models but requires phase 3 efficacy data. As a novel targeted therapy, it may complement existing antifibrotics, particularly for progressive phenotypes with hi…